RxSight, Inc. 8-K

What Happened
RxSight, Inc. announced on July 6, 2026 (Effective Date June 30, 2026) that it entered a License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd to develop and commercialize light‑adjustable versions of certain Alcon simultaneous vision intraocular lenses (SVIOLs) using RxSight Light Adjustable Technology™. Under the deal Alcon will pay a $60 million upfront cash payment and may pay additional milestone and royalty payments tied to feasibility, regulatory filings and approvals.

Key Details

• Effective Date: June 30, 2026; press release filed July 6, 2026 (Exhibit 99.1).
• Payments: $60M upfront; Alcon may pay a one‑time $70M Feasibility Milestone to continue the collaboration, $30M upon first U.S. FDA submission, and a one‑time $40M Approval Milestone at Alcon’s option upon approval.
• Royalties: Alcon will pay royalties of 30% on net sales of each Collaboration Product (subject to pre‑payment provisions, minimum royalty payments and customary adjustments).
• Roles: RxSight will manufacture and exclusively supply the Collaboration Products and will install/service Light Delivery Devices (LDDs) in the U.S.; RxSight will seek and retain U.S. regulatory approvals; Alcon will be primarily responsible for U.S. commercialization (RxSight may co‑promote upon certain triggers).
• Restrictions & adjustments: During development RxSight must prioritize the collaboration and is restricted from developing certain competing hybrid‑material SVIOLs. If RxSight later commercializes defined competing SVIOLs, Alcon’s payments to RxSight can be reduced (royalty reductions of 60%+ are possible), minimum royalties may be suspended, and RxSight may have to reimburse a portion of upfront/milestone payments (ranging from low double‑digit to high double‑digit percentages depending on timing).
• Term & termination: Agreement continues until the 10th anniversary of regulatory approval for the first Collaboration Product with automatic 5‑year renewals unless either party elects not to renew for specified reasons; either party can terminate for certain failures (e.g., nonpayment of milestone options, safety concerns, insolvency, material breach).

Why It Matters
This deal establishes a clear commercial pathway to combine RxSight’s Light Adjustable Technology with Alcon’s SVIOL platform, providing near‑term cash ($60M upfront) and the potential for sizable milestone and royalty revenue if development and regulatory milestones are met. For investors, the agreement shifts commercialization responsibility largely to Alcon while retaining RxSight’s manufacturing role and regulatory control in the U.S., but also includes restrictions and potential payment reductions if RxSight later pursues competing products. The transaction materially affects RxSight’s revenue prospects, R&D priorities and IP/competitive positioning.